dorsaVi Limited announced that Mathew Regan has commenced in his role as Group Chief Executive Officer, effective November 1, 2025. Mathew Regan joins dorsaVi with a proven track record in transforming emerging technologies into globally scalable platforms. His prior leadership roles include CEO of Artrya Limited and senior executive positions at Imdex, equipping him with extensive experience in scaling innovation across the digital health, artificial intelligence, and advanced manufacturing sectors. In his most recent role at Artrya, Mr. Regan successfully repositioned the company's AI driven clinical imaging platform, secured FDA clearances and enabled adoption by hospitals and clinicians globally.
Widely recognised for his ability to translate vision into delivery, Mr. Regan brings broad experience across digital health, artificial intelligence, advanced manufacturing, and IT infrastructure. Mr. Regan's appointment comes at a pivotal time for dorsaVi as the Company advances the commercialisation of its next-generation RRAM-enabled sensor architecture and explores broader applications through its Reflex platform1. These innovations underpin dorsaVi's strategy to expand beyond traditional clinical and workplace monitoring into high-growth verticals such as robotics, neuromorphic computing, and edge AI.
Mr. Regan's track record in scaling emerging technologies into global platforms makes him uniquely positioned to accelerate these initiatives, secure strategic partnerships, and unlock new commercial opportunities in both existing and adjacent markets. Andrew Ronchi will continue as CEO of dorsaVi's sensor division, focusing on scaling adoption of the Company's FDA-cleared movement analytics platform, driving U.S. commercial growth and strategic partnerships, and supporting integration of next-generation RRAM-enabled capabilities.
